| 155 | |
| Summary | Gut microbes (currently unknown members) affect Nivolumab's activity. |
| Gut | |
| Nivolumab (PubChem SID: 160698453) | |
| unknown | |
| 34876793 | |
| affect activity | |
| Nivolumab (anti-programmed cell death 1) is an immune therapy used to treat many types of cancer. The gut microbiome diversity greatly affects the nivolumab response. Hepatocellular carcinoma patients receiving nivolumab were classified as responders and non-responders according to the gut microbiome. the responders to the drug can be distinguished by several specific taxa like (Citrobacter freundii, Azospirillum sp., and Enterococcus durans) in their gut microbiome. While the non-responders had a high abundance of Dialister pneumosintes, Escherichia coli, Lactobacillus reteri, Streptococcus mutans, Enterococcus faecium, Streptococcus gordonii, Veillonella atypica, Granulicatella sp., and Trchuris trichiura). |
Browse Drug-Microbiome Relationship
Home